Last reviewed · How we verify

Metronidazole Suppositories

Dongfang Hospital Beijing University of Chinese Medicine · FDA-approved active Small molecule

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and protozoal DNA by generating reactive oxygen species after reduction of its nitro group.

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and protozoal DNA by generating reactive oxygen species after reduction of its nitro group. Used for Anaerobic bacterial infections of the colon and rectum, Protozoal infections (e.g., trichomoniasis, amebiasis), Bacterial vaginosis (local treatment).

At a glance

Generic nameMetronidazole Suppositories
SponsorDongfang Hospital Beijing University of Chinese Medicine
Drug classNitroimidazole antibiotic
TargetBacterial/protozoal DNA
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Metronidazole is reduced by anaerobic organisms and protozoa to form reactive intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is effective against anaerobic bacteria and certain parasites including Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia. The suppository formulation delivers the drug locally to the vaginal or rectal mucosa for topical antimicrobial effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: